Table 1. Characteristics of patients at the time of primary diagnosis (n = 104).
| Characteristics | Number | % |
|---|---|---|
| Age (median, range) | 46 (27–76) | |
| < 40 | 29 | 27.9 |
| 40–50 | 46 | 44.2 |
| > 50 | 29 | 27.9 |
| Primary surgery type | ||
| Mastectomy | 43 | 41.3 |
| Breast conserving surgery | 61 | 58.7 |
| Histology | ||
| Ductal | 92 | 88.5 |
| Non-ductal | 12 | 11.5 |
| Tumor nuclear grade | ||
| Low | 10 | 9.6 |
| Intermediate | 41 | 39.4 |
| High | 49 | 47.1 |
| Undescribed | 4 | 3.8 |
| Tumor size (pT) | ||
| pT1 (Tumor ≤ 20mm) | 62 | 59.6 |
| pT2-pT3 (Tumor > 20mm) | 41 | 39.4 |
| Nodal status (pN) | ||
| pN- (pN0) | 62 | 59.6 |
| pN+ (pN1, pN2, pN3) | 41 | 40.4 |
| Stage | ||
| IA | 45 | 43.3 |
| IIA-IIB | 41 | 39.4 |
| IIIA-IIIC | 18 | 17.3 |
| Subtype | ||
| HR+/HER2- | 56 | 53.8 |
| HER2+, irrespective of HR+/- | 26 | 25.0 |
| TNBC | 22 | 21.2 |
| Treatment of primary tumor | ||
| Adjuvant chemotherapy | 80 | 76.9 |
| Adjuvant radiotherapy | 76 | 73.1 |
| Adjuvant hormonal therapy | 62 | 59.6 |
HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, Triple negative breast cancer